StreetAlpha.app
Home › Stocks › PHIO

Phio Pharmaceuticals Corp. (PHIO)

$0.70
▼ −6.88%
LAST CLOSE · NOV 17

Phio Pharmaceuticals develops cancer treatments that use its INTASYL RNA technology to help the immune system attack tumors. It last closed at $0.70 on Nov 17, down 6.88% on the day.

AI Auto Pilots
Is PHIO in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Net income
−$14.7M
EPS (diluted)
−$1.21
Free cash flow
−$12.4M
Valuation
Market cap
$8.4M
12.0M shares
P/E
–
No P/E while losing money
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$10.6M
At Sep 30
Shareholder equity
$8.6M
Shares outstanding
12.0M
At Nov 3
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: −$13.3M−$13.3MFY2021FY2022: −$11.5M−$11.5MFY2022FY2023: −$10.8M−$10.8MFY2023FY2024: −$7.2M−$7.2MFY2024FY2025: −$8.7M−$8.7MFY2025

From PHIO's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 5). Last 12 months adds up the four latest quarters.

Last report
Nov 5
2026 · next date not on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
1 Buy
1 firm · not enough for a consensus
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Ratings · 90 days
1 Buy
1firm
1 Buy0 Hold0 Sell
Only 1 firm rated PHIO in the past 90 days, not enough for a consensus
Average 12-month target
$14.00
▲ 1894.0% upside

Based on 1 analyst who set a price target on PHIO in the past 90 days. The average target is $14.00, with a high of $14.00 and a low of $14.00, compared with the last close of $0.70.

Low $14.00Avg $14.00High $14.00
Blue marker: last close $0.70
Highest target$14.00
Average target$14.00
Lowest target$14.00
Latest rating changes
HC Wainwright & Co.Reiterated
Aug 26Buy$14
DateFirmActionRatingPrice target
Aug 26HC Wainwright & Co.ReiteratedBuy$14
Loading…

Technical Analysis

PHIO · as of the Nov 17 close · updated after every close
Downtrend, oversold

The stock is 20% below its 20 day and 32% below its 50 day average. It is 53% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 29), oversold. The nearest support is the 52 week low at $0.70, and the nearest resistance the Pivot at $0.71.

Short trendBearish
Long trendBearish
MomentumWeak
StretchOversold
VolatilityHigh, 8.7%/day
Key levels
$1.8852 week high+168.6%
$1.07200 day average+52.9%
$1.00100 day average+42.9%
$0.9350 day average+32.9%
$0.92Swing high (Nov 3)+31.4%
$0.8420 day average+20.0%
$0.73Pivot R1+4.3%
$0.71Pivot+1.4%
$0.7052 week low+0.0%
$0.70Last close
$0.69Pivot S1−1.4%
Indicators
RSI (14)29.05Oversold below 30Oversold
MACD-0.05Below its signal lineBearish
Stochastic9.8Near the bottom of its rangeOversold
ADX (14)19.3No clear trend
Williams %R-100.0Oversold below −80, overbought above −20Oversold
CCI (20)-200.2Oversold below −100, overbought above 100Oversold
Rate of change−22.3%Change over 10 sessionsBearish
ATR (14)$0.06Typical daily range, 8.7% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for PHIO

What happened before

See how PHIO did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow PHIO usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How PHIO has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2008.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in PHIO in the last 90 days.

Loading…

See today’s whale options flow across the market →

PHIO Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Strongly bullish
Strongly bearishNeutralStrongly bullish
  • ▲11 buying vs 9 selling
  • ▲Held by funds +1.2 pts
  • ▲Funds holding +2
  • ▲Superinvestors: 2 added, 0 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding2624+8.3%
In funds' top 1000–
Held by funds6.6%5.4%+1.2 pts
New / increased4 / 74 / 6+10.0%
Reduced / sold out7 / 28 / 4−25.0%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See PHIO institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether PHIO is in one of them and how their past PHIO trades turned out.

PHIO in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered PHIO in an article yet. Here's the latest on the wider market.

About Phio Pharmaceuticals

Phio Pharmaceuticals is a clinical stage biopharmaceutical company based in King of Prussia, Pennsylvania. It is developing cancer treatments based on its INTASYL small interfering RNA technology, which is designed to silence proteins that reduce the immune system's ability to attack tumors. Its lead candidate, PH-762, is being tested in a clinical trial in patients with skin cancers, including cutaneous squamous cell carcinoma and melanoma. The therapies are designed for patients with cancer and are given by injection directly into tumors.

Headquarters
King Of Prussia, PA